Given these potential barriers, multigene panel testing that includes LS testing for patients with ovarian cancer is more cost and time efficient than initial MMR staining and separate high‐penetrance breast and/or ovarian susceptibility germline testing, especially for women with non‐serous, non‐mucinous ovarian cancer. Here, MRC1 is linked to ovarian carcinoma.